BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16314690)

  • 1. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
    Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
    J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.
    Fujimura T; Sakuma H; Ohkubo-Suzuki A; Aramori I; Mutoh S
    Biol Pharm Bull; 2006 Mar; 29(3):423-9. PubMed ID: 16508139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
    Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
    Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
    Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.
    Yu C; Markan K; Temple KA; Deplewski D; Brady MJ; Cohen RN
    J Biol Chem; 2005 Apr; 280(14):13600-5. PubMed ID: 15691842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
    Zhou G; Cummings R; Li Y; Mitra S; Wilkinson HA; Elbrecht A; Hermes JD; Schaeffer JM; Smith RG; Moller DE
    Mol Endocrinol; 1998 Oct; 12(10):1594-604. PubMed ID: 9773982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
    Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
    Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.
    Wang Y; Porter WW; Suh N; Honda T; Gribble GW; Leesnitzer LM; Plunket KD; Mangelsdorf DJ; Blanchard SG; Willson TM; Sporn MB
    Mol Endocrinol; 2000 Oct; 14(10):1550-6. PubMed ID: 11043571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators.
    Kodera Y; Takeyama K; Murayama A; Suzawa M; Masuhiro Y; Kato S
    J Biol Chem; 2000 Oct; 275(43):33201-4. PubMed ID: 10944516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers.
    Samarasinghe SP; Sutanto MM; Danos AM; Johnson DN; Brady MJ; Cohen RN
    Obesity (Silver Spring); 2009 May; 17(5):965-72. PubMed ID: 19165156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators.
    Yang W; Rachez C; Freedman LP
    Mol Cell Biol; 2000 Nov; 20(21):8008-17. PubMed ID: 11027271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.
    Li M; Pascual G; Glass CK
    Mol Cell Biol; 2000 Jul; 20(13):4699-707. PubMed ID: 10848596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.